| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jing Chen | |
| Chana L Glasser | |||
| P2860 | cites work | Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy | Q26766341 |
| Targeting the leukemia-stroma interaction in acute myeloid leukemia: rationale and latest evidence | Q26770388 | ||
| Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance | Q26776393 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Potent inhibition of DOT1L as treatment of MLL-fusion leukemia | Q27678800 | ||
| Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia | Q28257174 | ||
| Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 | Q29615851 | ||
| Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial | Q30315977 | ||
| TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. | Q31109634 | ||
| Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells | Q33297414 | ||
| Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study | Q33400617 | ||
| Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study | Q33442949 | ||
| Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia | Q34052520 | ||
| Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia | Q34095013 | ||
| Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. | Q34172042 | ||
| Preclinical efficacy of MEK inhibition in Nras-mutant AML. | Q34737521 | ||
| Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic | Q34817365 | ||
| Challenges and opportunities in targeting the menin-MLL interaction | Q35122366 | ||
| Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo | Q35557914 | ||
| MDM2, an introduction. | Q35621040 | ||
| MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy | Q35848425 | ||
| MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. | Q35898171 | ||
| Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 | Q36132787 | ||
| Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program | Q36392660 | ||
| MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. | Q37633585 | ||
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
| Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia | Q38068816 | ||
| Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting | Q38227885 | ||
| The MLL recombinome of acute leukemias in 2017. | Q38681972 | ||
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | Q38712298 | ||
| Antibody-Based Treatment of Acute Myeloid Leukemia | Q38979277 | ||
| Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect | Q39006265 | ||
| Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review | Q39043759 | ||
| TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes | Q39555179 | ||
| Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study | Q39822035 | ||
| Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial | Q40386036 | ||
| Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia | Q40405651 | ||
| Signal transduction through MAP kinase cascades | Q41750250 | ||
| The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia | Q43857606 | ||
| The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. | Q46135008 | ||
| Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies | Q46332183 | ||
| A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study | Q46902471 | ||
| A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia | Q47563820 | ||
| Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo | Q50118866 | ||
| Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. | Q50477441 | ||
| FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. | Q52591098 | ||
| Investigational CD33-targeted therapeutics for acute myeloid leukemia. | Q52657685 | ||
| Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. | Q52725969 | ||
| Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. | Q53446336 | ||
| Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models | Q57821553 | ||
| Targeting mesothelin in ovarian cancer | Q59799473 | ||
| Mutant p53 as a guardian of the cancer cell | Q60959628 | ||
| New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise | Q64253519 | ||
| Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells | Q73209112 | ||
| AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group | Q84567924 | ||
| A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells | Q88376169 | ||
| The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia | Q88561872 | ||
| FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | Q90239869 | ||
| Molecular Approaches to Treating Pediatric Leukemias | Q90293123 | ||
| A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML | Q90473342 | ||
| Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML | Q91007369 | ||
| A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia | Q91379494 | ||
| MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388) | Q91755518 | ||
| The role of TP53 in acute myeloid leukemia: Challenges and opportunities | Q92496678 | ||
| Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia | Q93131786 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | acute myeloid leukemia | Q264118 |
| childhood acute myeloid leukemia | Q55779816 | ||
| P577 | publication date | 2020-02-10 | |
| P1433 | published in | Children (Basel, Switzerland) | Q27726177 |
| P1476 | title | New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML) | |
| P478 | volume | 7 |
Search more.